FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Paxil back on the market; Tarceva gets European recommendation; and much more...

Tools

> GlaxoSmithKline has returned Paxil CR to the market, three months after regulators found manufacturing problems at three of its facilities. Story

> A European drug panel has recommended Roche's Tarceva for lung cancer. Story

> The European Medicines Agency has recommended the continued suspension of Pfizer's Bextra with new warnings regarding all Cox-2 inhibitors. Story

> Neurobiological Technologies has signed a manufacturing deal with Baxter and Nordmark for a Phase III trial of Viprinex. Release

> Switzerland's Debiopharm and Neovacs have signed an equity and licensing deal for the development of Neovacs' anti-TNF-Alpha product. Release

> The EU's Committee for Medicinal Products for Human Use has recommended approval of Schering's contrast agent, Vasovist. Article

And Finally... Even as pharmaceutical drugs continue their double-digit rise in prices, generic drug prices are remaining steady. Story

Bookmark and Share
Get Your FREE FierceBiotech Email Newsletter:

More stories about GlaxoSmithKline   Generics   EMEA   cox 2 inhibitor   Bayer Schering   Tarceva   Phase III